Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review

Mutations in the epidermal growth factor receptor (EGFR) are drivers of a subset of lung cancers. In recent years, the treatment of non‐small cell lung cancer (NSCLC), especially with EGFR inhibitors, has made rapid progress, and the median progression‐free survival (PFS) of patients with EGFR gene‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Cuicui, Lin, Li, Zuo, Ran, Wang, Yajie, Chen, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471019/
https://www.ncbi.nlm.nih.gov/pubmed/32776462
http://dx.doi.org/10.1111/1759-7714.13606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471019/
https://www.ncbi.nlm.nih.gov/pubmed/32776462
http://dx.doi.org/10.1111/1759-7714.13606

Ejemplares similares